Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 May 2013

Bajaj Preeti S, Veenstra David L

Abstract excerpt

PURPOSE: We sought to assess the benefits, risks, and personal utility of factor V Leiden mutation testing to improve pregnancy outcomes and to assess the utility of decision-analytic modeling for complex outcomes in genomics. METHODS: We developed a model to evaluate factor V Leiden testing amon...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Decision Support Techniques
Share to Decision Trees

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor V

Share to Genomics

Share to Pregnancy Outcome

Share to Quality-Adjusted Life Years

Share to United States

Source

Identifiers

PMID: 23138100
DOI: 10.1038/gim.2012.139

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23138100-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics.PMID 23138100Read ↗

Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations.Semantic proximity Read ↗

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.Semantic proximity Read ↗

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.Semantic proximity Read ↗

Gene therapy in hemophilia A: a cost-effectiveness analysisSemantic proximity Read ↗

Cost savings through molecular diagnosis for hereditary hemorrhagic telangiectasia.Semantic proximity Read ↗

Preferences regarding contemporary prenatal genetic tests among women desiring testing: implications for optimal testing strategiesSemantic proximity Read ↗

Stakeholder perspectives on a risk-benefit framework for genetic testing.Semantic proximity Read ↗

Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.Semantic proximity Read ↗

Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland.Semantic proximity Read ↗

Preferences of women facing a prenatal diagnostic choice: long-term outcomes matter mostSemantic proximity Read ↗

Outcomes of genetic testing in adults with a history of venous thromboembolism.Semantic proximity Read ↗

Genetic screening for the predisposition to venous thromboembolism: a cost-utility analysis of clinical practice in the Italian health care system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.